Nine researchers at Fred Hutch Cancer Center will receive a total of $1.175 million in funding for early-stage research projects as part of Fred Hutch’s Evergreen Fund, an internal grant program designed to accelerate translational science and foster strategic industry collaborations.
An advisory board of biotech leaders, venture capitalists and other members of the life sciences industry chose the projects to receive funding based on their potential to move from the lab bench to the clinic and commercial market. The projects include cell therapies for pancreatic cancer, a treatment for advanced prostate cancer, new biomarkers for esophageal cancer, and antibody treatment for herpes simplex virus.
